Narrow search
Showing 1 - 10 of 53
Cover Image
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225
Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board - LFN (now called the Dental and Pharmaceutical Benefits agency - TLV) since 2002. VBP has the character of a monopoly system, leading to reimbursement...
Persistent link: https://www.econbiz.de/10010552620
Cover Image
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225
Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board — LFN (now called the Dental and Pharmaceutical Benefits agency — TLV) since 2002. VBP has the character of a monopoly system, leading to...
Persistent link: https://www.econbiz.de/10011000768
Cover Image
Kostnadseffektivitetsanalyser : ett instrument för en långsiktigt hållbar läkemedelsmarknad?
Persson, Ulf; Nordling, Sara; Pettersson, Billie - In: Ekonomisk debatt 37 (2009) 3, pp. 42-53
Persistent link: https://www.econbiz.de/10003834375
Cover Image
Kostnadseffektivitetsanalyser : ett instrument för en långsiktigt hållbar läkemedelsmarknad?
Persson, Ulf; Nordling, Sara; Pettersson, Billie - In: Ekonomisk debatt 37 (2009) 3, pp. 42-53
Persistent link: https://www.econbiz.de/10009917155
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: Evidence from longitudinal, disease-level data
Lichtenberg, Frank; Pettersson, Billie - 2012
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10010283600
Cover Image
The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data
Lichtenberg, Frank; Pettersson, Billie - CESifo - 2012
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10010569681
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data
Lichtenberg, Frank R.; Pettersson, Billie - In: Economics of Innovation and New Technology 23 (2014) 3, pp. 239-273
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10010952230
Cover Image
Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden
Pettersson, Billie; Hoffmann, Mikael; Andersson, David; … - In: Health Policy 108 (2012) 2, pp. 207-215
A new reimbursement scheme (RS) for glucose lowering therapies (GLT) was implemented in Sweden on March 1, 2010. Products on the market were retained, restricted, excluded or excluded for new courses in the new RS. The aim of this study was to compare utilization and costs of GLT for type 2...
Persistent link: https://www.econbiz.de/10011048419
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010 : evidence from longitudinal, disease-level data
Lichtenberg, Frank R.; Pettersson, Billie - 2012
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10009571756
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997 - 2010 : evidence from longitudinal, disease-level data
Lichtenberg, Frank R.; Pettersson, Billie - In: Economics of innovation and new technology 23 (2014) 3/4, pp. 239-273
Persistent link: https://www.econbiz.de/10010407486